Alpha1-fetoprotein in neonatal hepatobiliary disease

Area of Science:

• Pediatric Gastroenterology
• Hepatology
• Neonatal Medicine

Background:

• Distinguishing neonatal hepatitis syndrome from biliary atresia is crucial for timely intervention.
• Serum alpha-1-fetoprotein (AFP) has been proposed as a potential biomarker.

Purpose of the Study:

• To evaluate the diagnostic utility of serum AFP levels in differentiating neonatal hepatitis from biliary atresia and other hepatopathies in infants.
• To determine age-specific AFP cutoffs for improved diagnostic accuracy.

Main Methods:

• Serum AFP concentrations were measured in 52 neonates and infants with diagnosed hepatobiliary disorders.
• Patients were categorized into three groups: neonatal hepatitis syndrome, biliary atresia, and other hepatopathies (e.g., choledochal cyst).
• Statistical analysis was performed to compare mean AFP levels across groups and assess the impact of patient age.

Main Results:

• Mean serum AFP was significantly higher in patients with neonatal hepatitis compared to those with biliary atresia or other hepatopathies.
• Infants aged 1-4 months with AFP > 35 µg/ml were suggestive of neonatal hepatitis.
• Infants < 4 months with AFP < 10 µg/ml suggested biliary atresia or other non-hepatitis hepatopathies.
• Significant overlap in AFP values between 10-35 µg/ml limits definitive diagnosis.

Conclusions:

• Serum AFP levels show potential in differentiating neonatal hepatitis from biliary atresia, particularly with age-specific interpretation.
• AFP levels greater than 35 µg/ml in infants 1-4 months strongly suggest neonatal hepatitis.
• AFP levels below 10 µg/ml in infants < 4 months may indicate biliary atresia or other hepatopathies, but overlapping values necessitate caution.